6CM
PMN icon

683 Capital Management’s ProMIS Neurosciences PMN Stock Holding History

683 Capital Management’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
95,000
+2,150
+2% +$23.3K 0.06% 120
2026
Q1 		$1.18M Buy
+92,850
New +$1.38M 0.06% 133

Other funds holding PMN

JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

683 Capital Management's PMN Position: Q2 2026 in Review

683 Capital Management increased its ProMIS Neurosciences (PMN) stake by 2.3% in Q2 2026, buying an estimated $23.3K and bringing the position to 95,000 shares worth $1.25M. The position accounts for 0.06% of the portfolio, ranked #120.

683 Capital Management first reported a position in PMN in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

  • 683 Capital Management held 95,000 shares of ProMIS Neurosciences worth $1.25M as of Q2 2026.
  • 683 Capital Management bought 2,150 ProMIS Neurosciences shares in Q2 2026, an estimated $23.3K.
  • ProMIS Neurosciences made up 0.06% of 683 Capital Management's portfolio in Q2 2026, its #120 holding.
  • 683 Capital Management first reported a position in ProMIS Neurosciences in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.